JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

Merck & Co Inc.

Open

SectorHealthcare

118.3 2.18

Overview

Share price change

24h

Current

Min

115.89

Max

120.31

Key metrics

By Trading Economics

Income

1.4B

5.8B

Sales

1.5B

17B

P/E

Sector Avg

14.996

90.422

EPS

2.58

Dividend yield

2.9

Profit margin

33.497

Employees

73,000

EBITDA

1.8B

8.2B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+5.8% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.90%

2.13%

Next Earnings

23 kwi 2026

Next Dividend date

7 kwi 2026

Next Ex Dividend date

16 mar 2026

Market Stats

By TradingEconomics

Market Cap

63B

283B

Previous open

116.12

Previous close

118.3

News Sentiment

By Acuity

39%

61%

122 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Merck & Co Inc. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 lut 2026, 11:45 UTC

Earnings

Merck Expects Slower Earnings Growth As It Spends on Acquisitions

3 lut 2026, 19:56 UTC

Earnings

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 lut 2026, 19:43 UTC

Earnings

Merck Stock Gains as Earnings Top Estimates. 'Momentum Is Building,' Says CEO. -- Barrons.com

3 lut 2026, 16:01 UTC

Earnings

Merck Stock Gains as Earnings Top Estimates. 'Momentum Is Building,' Says CEO. -- Barrons.com

3 lut 2026, 14:19 UTC

Earnings

Merck Earnings Top Estimates. Why the Stock Is Falling. -- Barrons.com

3 lut 2026, 12:17 UTC

Earnings

Merck Earnings Top Estimates. Why the Stock Is Falling. -- Barrons.com

3 lut 2026, 11:48 UTC

Earnings

Merck Earnings Top Estimates. Why the Stock Is Falling. -- Barrons.com

3 lut 2026, 11:30 UTC

Earnings

Merck: Have Committed More Than $70B in Capital and R&D Spending to Strengthen U.S. Production and Innovation >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-January 2026 Exchange Rates >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: Also Reached Understanding With Commerce Dept to Delay Section 232 Tariffs for 3 Years, Enabling Co to Make Investments in U.S. to Reshore Manufacturing for American Patients >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: Plans to Provide Key Products Through Direct-To-Patient Program at Affordable Prices for Eligible Patients in U.S. >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: Reach Agreement With U.S. Government Intended to Lower Medicine Costs for Americans >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q Winrevair Sales $467M, Up 133% and Reflecting Continued Uptake in U.S and Early Launch Uptake in Certain Intl Mkts >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: Adj EPS Outlook Also Reflects One-Time Charge of About $3.65/Shr for Acquisition of Cidara >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck Sees 2026 Adj EPS $5-Adj EPS $5.15 >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-January 2026 Exchange Rates >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck Sees 2026 Sales $65.5B-$67B >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: Latest 4Q Results Include a Charge of 5c/Share for Acquisition of MK-8690 Sole Global Rights >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: Lower 4Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China, Lower Sales in Japan Following Natl Catch-Up Immunization Pgm >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q Gardasil/Gardasil 9 Sales Down 34% >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q Keytruda Sales Up 7% >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: 4Q Animal Health Sales Growth Primarily Due to Higher Demand of Livestock Products >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck: Transformation of Our Portfolio, Bolstered by Acquisitions of Verona Pharma and Cidara Therapeutics, Is Well Under Way >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q Gardasil/Gardasil 9 Sales $1.03B >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q Animal Health Sales Up 8% >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q Pharmaceutical Sales Up 6% >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q Januvia/Janumet Sales Up 3% >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q Adj EPS $2.04 >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q Pharmaceutical Sales $14.84B >MRK

3 lut 2026, 11:30 UTC

Earnings

Merck 4Q EPS $1.19 >MRK

Peer Comparison

Price change

Merck & Co Inc. Forecast

Price Target

By TipRanks

5.8% upside

12 Months Forecast

Average 119.95 USD  5.8%

High 139 USD

Low 95 USD

Based on 19 Wall Street analysts offering 12 month price targets forMerck & Co Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

12

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

76.03 / 83.28Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

122 / 352 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat